Processes should be benchmarked against other regulators, including CAA & ONR.

Auditors must be from outside of the pharmaceutical industry & have no industry links.

A wide range of medicines & devices have caused patient harm. These have been approved by MHRA. It has often taken years to react to safety signals e.g. mesh, Primodos & Valproate.

We believe the MHRA is focusing too much on clinical trials of new medicines, rather than safety of existing ones.

There is a 'revolving door' between industry & the regulator, several board members declare conflicts of interest.

MHRA is primarily funded by the pharmaceutical industry.